development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b
clinical trial of SNS-595 in combination with cytarabine in relapsed
or refractory AML patients is in progress. Sunesis plans to begin
enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose
schedule in previously untreated elderly AML patients in the first
half of 2008. Sunesis expects to report data later this year for
both AML clinical trials.
-- Results from a non-clinical study of SNS-032, a potent and selective
inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented
at ASH. These data demonstrated that SNS-032 induces apoptosis in
chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in
vitro activity compared favorably with flavopiridol in CLL cells
obtained from patients. SNS-032 currently is in a Phase 1 clinical
trial of patients with relapsed or refractory CLL or multiple myeloma.
To date, the drug has been well tolerated in this trial, and dose
escalation in both indications is expected to be completed this year.
-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial
of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and
C, in advanced solid tumors. To date, SNS-314 has been well tolerated
and no dose-limiting toxicities have been observed. The company
expects to identify a maximum-tolerated dose in this Phase 1 clinical
trial this year.
-- In December, Sunesis and the Multiple Myeloma Research Consortium
(MMRC) announced a collaboration to evaluate the preclinical activity
of SNS-032 in multiple myeloma-relevant models and in primary disease
tissue, extending non-clinical studies performed by Sunesis.
-- In February 2008, Sunesis received
|SOURCE Sunesis Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved